Pfizer wil_老虎社区_美港股上老虎

2021-12-24

Pfizer will continue to soar short term. There are so little competition for vaccines.

How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":698360236,"tweetId":"698360236","gmtCreate":1640306326685,"gmtModify":1640306391646,"author":{"id":3574715322913604,"idStr":"3574715322913604","authorId":3574715322913604,"authorIdStr":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Pfizer will continue to soar short term. There are so little competition for vaccines.&nbsp;</body></html>","htmlText":"<html><head></head><body>Pfizer will continue to soar short term. There are so little competition for vaccines.&nbsp;</body></html>","text":"Pfizer will continue to soar short term. There are so little competition for vaccines.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698360236","repostId":1172289344,"repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohu8.com/m/news/1172289344?lang=zh_CN&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"Pfizer, Inc.&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;Paxlovid,&nbsp;has been authorized for use by the U.S. Food and Drug Administration.<blockquote>辉瑞公司。周三宣布推出口服COVID-19抗病毒药物，帕克斯洛维德、已被美国授权使用。食品和药物管理局。</blockquote> The Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.<blockquote>辉瑞分析师：SVB Leerink分析师Geoffrey Porges给予辉瑞市场表现评级和52美元的目标价。</blockquote> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.<blockquote>美银证券分析师Geoff Meacham维持中性评级和59美元的目标价。</blockquote> Broad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;Merck &amp; Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.<blockquote>广泛的标签，增加供应使辉瑞占据主导市场地位：辉瑞公司提前获得了口服COVID-19治疗的认可默克公司。Porges在一份报告中表示，该公司比辉瑞公司提前一个多月提交了molnupiravir的申请。</blockquote> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.<blockquote>该分析师认为，辉瑞明年Paxlovid的预期供应量增加至1.2亿个疗程意义重大。该分析师表示，该公司将销售和分销其中大部分课程，其收入将远远超过SVB Leerink目前预测的2022年Paxlovid销售额240亿美元和2023年330亿美元。</blockquote> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.<blockquote>该分析师表示，2024年收入贡献将降至100亿美元。他补充说，预计2022-24年Paxlovid总销售额为670亿美元，远高于共识。</blockquote> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.<blockquote>Porges说，药物间相互作用对Paxlovid摄取的影响不大，因为清单上的许多药物可以在Paxlovid治疗的短期内暂停，而不会对患者产生重大影响。他补充说，可能被排除在Paxlovid使用之外的患者是那些患有严重肝或肾功能损害的患者以及那些HIV-1感染未得到控制的患者。</blockquote> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.<blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并且与默克公司的molnupiravir相比，其风险/益处相对良性，后者显示了动物的胚胎发育和胎儿生长风险。</blockquote> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.<blockquote>Paxlovid比一些领先的抗体疗法具有更好的疗效，并且由于一些抗体疗法已经失去了针对奥密克戎病毒变异体的疗效，Paxlovid将是“对医生和患者来说非常有吸引力的选择”，Porges说。</blockquote> Paxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.<blockquote>美国银行表示，Paxlovid应该仍然是稳定的贡献者：美国银行分析师米查姆表示，到2022年销售辉瑞生产的每一个疗程的Paxlovid应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在2022年确认每剂疫苗的收入。</blockquote> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.<blockquote>分析师表示，从长远来看，Paxlovid可能仍然是一个稳定的贡献者。</blockquote> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.<blockquote>“我们预计突破性感染将在流行阶段定期继续，虽然疫苗和先前感染的基线免疫力水平将限制严重程度，但我们预计在高危个体中发生的新冠病例的治疗将成为标准护理，”米查姆说。</blockquote> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.<blockquote>分析师表示，预计政府实体将储备默克的药物，因此初步销售可能会出现。他补充说，从长远来看，Paxlovid可能是首选药物。</blockquote> Pfizer Price Action:&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.<blockquote>辉瑞价格走势：辉瑞股价周四收盘下跌1.41%，至58.71美元。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga \n2021-12-24 07:26\n</div>\n</div>\n</h4>\n</header>\n<article>\nPfizer, Inc.&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;Paxlovid,&nbsp;has been authorized for use by the U.S. Food and Drug Administration.<blockquote>辉瑞公司。周三宣布推出口服COVID-19抗病毒药物，帕克斯洛维德、已被美国授权使用。食品和药物管理局。</blockquote> The Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.<blockquote>辉瑞分析师：SVB Leerink分析师Geoffrey Porges给予辉瑞市场表现评级和52美元的目标价。</blockquote> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.<blockquote>美银证券分析师Geoff Meacham维持中性评级和59美元的目标价。</blockquote> Broad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;Merck &amp; Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.<blockquote>广泛的标签，增加供应使辉瑞占据主导市场地位：辉瑞公司提前获得了口服COVID-19治疗的认可默克公司。Porges在一份报告中表示，该公司比辉瑞公司提前一个多月提交了molnupiravir的申请。</blockquote> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.<blockquote>该分析师认为，辉瑞明年Paxlovid的预期供应量增加至1.2亿个疗程意义重大。该分析师表示，该公司将销售和分销其中大部分课程，其收入将远远超过SVB Leerink目前预测的2022年Paxlovid销售额240亿美元和2023年330亿美元。</blockquote> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.<blockquote>该分析师表示，2024年收入贡献将降至100亿美元。他补充说，预计2022-24年Paxlovid总销售额为670亿美元，远高于共识。</blockquote> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.<blockquote>Porges说，药物间相互作用对Paxlovid摄取的影响不大，因为清单上的许多药物可以在Paxlovid治疗的短期内暂停，而不会对患者产生重大影响。他补充说，可能被排除在Paxlovid使用之外的患者是那些患有严重肝或肾功能损害的患者以及那些HIV-1感染未得到控制的患者。</blockquote> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.<blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并且与默克公司的molnupiravir相比，其风险/益处相对良性，后者显示了动物的胚胎发育和胎儿生长风险。</blockquote> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.<blockquote>Paxlovid比一些领先的抗体疗法具有更好的疗效，并且由于一些抗体疗法已经失去了针对奥密克戎病毒变异体的疗效，Paxlovid将是“对医生和患者来说非常有吸引力的选择”，Porges说。</blockquote> Paxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.<blockquote>美国银行表示，Paxlovid应该仍然是稳定的贡献者：美国银行分析师米查姆表示，到2022年销售辉瑞生产的每一个疗程的Paxlovid应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在2022年确认每剂疫苗的收入。</blockquote> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.<blockquote>分析师表示，从长远来看，Paxlovid可能仍然是一个稳定的贡献者。</blockquote> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.<blockquote>“我们预计突破性感染将在流行阶段定期继续，虽然疫苗和先前感染的基线免疫力水平将限制严重程度，但我们预计在高危个体中发生的新冠病例的治疗将成为标准护理，”米查姆说。</blockquote> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.<blockquote>分析师表示，预计政府实体将储备默克的药物，因此初步销售可能会出现。他补充说，从长远来看，Paxlovid可能是首选药物。</blockquote> Pfizer Price Action:&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.<blockquote>辉瑞价格走势：辉瑞股价周四收盘下跌1.41%，至58.71美元。</blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2041,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["PFE"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":73,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/698360236"}